Hologic Inc. has seen mixed developments in the past year. The
bio-tech company returned
21% to shareholders in the past year and BTIG has maintained a hold rating for the stock.
Vanguard realignment shows zero shares after January 2026. Astute investment debate, revolving between Hologic and
ALGN with respect to better investment pick, persists in the
medtech market. Syquant Capital Sas and
SG Americas Securities LLC have recently purchased new stakes in HOLX. Dissenting views share reasons to sell HOLX, even suggesting alternatives. Active searches for HOLX was observed by investors, indicated by significant search volumes. There have been substantial fluctuations in the valuation of HOLX with repeated assessment of valuation after share price momentum and stability. The biggest highlight is the
$18.3 billion takeover offer from
Blackstone and TPG, which resulted in a temporary surge of 7.7% in HOLX's share price. Q4 earnings of HOLX came above expectations. However, missed revenue estimates for Q4 CY2025 have also been in recent news, leading to adjustments in price targets by market analysts. HOLX is all set to go private with regulatory approval already in place. Shareholders have backed the sale to Blackstone and TPG but it's facing legal challenges amid merger.
Hologic HOLX News Analytics from Wed, 20 Aug 2025 07:00:00 GMT to Fri, 27 Mar 2026 15:23:53 GMT -
Rating -1
- Innovation -2
- Information 7
- Rumor -7
